KIITEE Phase 1 Results 2025 has been declared at kiitee.kiit.ac.in. The direct link to check is given below. The Kalinga Institute of Industrial Technology, KIIT, has declared the KIITEE 2025 ...

GUBamy was well tolerated with adverse events being predominantly GI related, mild and consistent with data from the SAD study. Doses of 1 mg and 2 mg ... first part of the MAD study are very ...

today announced initial topline results from the Phase 1 clinical trial of KER-065 in healthy volunteers. Topline results from this ongoing trial are through the multiple ascending dose (“MAD ...

The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary ...

Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported ... uncertainties inherent in the initiation, timing and design of future clinical trials, the availability ...

MetaVia (MTVA) announced positive results from the 4-week multiple ascending dose Part 2 of its Phase 1 clinical trial of DA-1726 ... In the 28-day, 36-subject MAD portion of the study, DA ...

The presentation will include safety findings from the Phase 1 single- and multiple ... of planned clinical trials of our product candidates and our proposed design of future clinical trials ...

The MAD portion of the study enrolled healthy adults with a minimum body mass index between BMI 30 – 45 kg/m 2. The primary endpoint of the Phase 1 trial ... on this clinical trial, please ...

In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 ...